Blincyto (blinatumomab)

pCPA File Number: 21121
Negotiation Status:
Concluded with an LOI
Indication(s):
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
pCODR 10146
pCPA Engagement Letter Issued:
Negotiation Process Concluded: